Detalhe da pesquisa
1.
Pharmacogenomics with red cells: a model to study protein variants of drug transporter genes.
Vox Sang
; 116(2): 141-154, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-32996603
2.
Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro.
Proc Natl Acad Sci U S A
; 110(31): 12703-8, 2013 Jul 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-23858438
3.
Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma.
Proc Natl Acad Sci U S A
; 110(12): E1083-91, 2013 Mar 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-23471984
4.
VB-111 (ofranergene obadenovec) in combination with nivolumab in patients with microsatellite stable colorectal liver metastases: a single center, single arm, phase II trial.
J Immunother Cancer
; 12(1)2024 01 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38184304
5.
Targeting neddylation sensitizes colorectal cancer to topoisomerase I inhibitors by inactivating the DCAF13-CRL4 ubiquitin ligase complex.
Nat Commun
; 14(1): 3762, 2023 06 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-37353483
6.
Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial.
Clin Cancer Res
; 29(18): 3603-3611, 2023 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37227187
7.
Reply to D'Amato et al. and Zeldis et al.: Screening of thalidomide derivatives in chicken and zebrafish embryos.
Proc Natl Acad Sci U S A
; 110(50): E4820, 2013 Dec 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-24471177
8.
Whole-exome sequencing reveals germline-mutated small cell lung cancer subtype with favorable response to DNA repair-targeted therapies.
Sci Transl Med
; 13(578)2021 01 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-33504652
9.
Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer.
J Immunother Cancer
; 9(3)2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33664086
10.
Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress.
Cancer Cell
; 39(4): 566-579.e7, 2021 04 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33848478
11.
U.S. Public Health Service Commissioned Corps pharmacists: making a difference in advancing the nation's health.
J Am Pharm Assoc (2003)
; 49(3): 446-52, 2009.
Artigo
em Inglês
| MEDLINE | ID: mdl-19443327
12.
A Pilot Study of Liposomal Doxorubicin Combined with Bevacizumab followed by Bevacizumab Monotherapy in Patients with Advanced Kaposi Sarcoma.
Clin Cancer Res
; 25(14): 4238-4247, 2019 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30979736
13.
Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population.
Prostate Cancer Prostatic Dis
; 22(3): 406-410, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30542053
14.
HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer.
J Clin Invest
; 128(8): 3333-3340, 2018 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29939161
15.
Pharmacologic biomarkers in the development of stratified cancer medicine.
Clin Cancer Res
; 20(10): 2525-9, 2014 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24831275
16.
Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers.
J Clin Pharmacol
; 54(8): 865-73, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24710841
17.
A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors.
Clin Cancer Res
; 18(8): 2344-51, 2012 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22371451
18.
Assessing progress against prostate cancer.
Clin Genitourin Cancer
; 5(2): 102-3, 2006 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-17026796
19.
The Role of Wild-Type p53 in Cisplatin-Induced Chk2 Phosphorylation and the Inhibition of Platinum Resistance with a Chk2 Inhibitor.
Chemother Res Pract
; 2011: 715469, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-22312557
20.
SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer.
J Clin Oncol
; 29(18): 2565-73, 2011 Jun 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-21606417